Sell-Side Analysts: 11 Stocks Rated “Buy” by UBS, Deutsche, Barclays and other Big Names

Sell-Side Analysts: 11 Stocks Rated “Buy” by UBS, Deutsche, Barclays and other Big Names

Research  these Stocks on Kapitall’s Playground Now

 
research now

A Sell-Side Analyst works for a brokerage to compose reports and forecast the markets for their clients.  They’ll typically focus on a specific industry and produce regular reports containing predictions on commodity prices and expected performance for a stock.

Main Street investors benefit from sell-side analyst reports since seasoned experts typically write them. Better yet, sell-side research as a whole outperforms that of buy-side. Investors place their faith in sell-side ratings because the reports are not tailored for a specific client, but to all the clients of the brokerage. The analyst and the firm’s reputation can stand on the line with each “buy,” “sell” or “hold” rating.

But be warned, every report produced by a sell-side analyst is called a “blanket recommendation” because they do not take into account the wants and needs of every individual. Investors must therefore determine if they are applicable to their own portfolio.

And don’t forget, the analyst is paid by the brokerage, not the clients themselves, the report could be part of an agenda of the firm that you don’t know about.  So remember to measure twice and cut once because their reports do not necessarily provide proper advice for an individual investor.

Business Section: Investing Ideas

Through word of mouth and social media no recommendation is necessarily a secret to investors everywhere. We gathered the sell-side analyst ratings from reputable firms including Argus, Barclays, Canaccord Genuity, Collins Stewart, Deutsche, Needham, Oppenheimer, Robert W Baird, UBS, and Wedbush.

We then screened for the stocks that had “buy” “Outperform” or “Overweight” ratings from at least three of those names. Eleven stocks made the cut. We list them below.

What do you think, are sell-side analysts making the right call with these names?

Interactive Chart: Use the Compar-O-Matic to compare average analyst ratings for the stocks mentioned below:

“1. Aegerion Pharmaceuticals, Inc. (AEGR, Earnings, Analysts, Financials): Engages in the development and commercialization of novel therapeutics to treat severe lipid disorders. Market cap at $301.31M, most recent closing price at $14.41. On 11/09/2011, Deutsche Bank had a Buy rating on the stock. On 05/22/2012, Needham had a Buy rating on the stock. On 03/26/2012, Canaccord Genuity had a Buy rating on the stock.

 

“2. The Allstate Corporation (ALL, Earnings, Analysts, Financials): Engages in the personal property and casualty insurance, life insurance, retirement, and investment products businesses primarily in the United States. Market cap at $16.25B, most recent closing price at $33.07. On 12/02/2011, Deutsche Bank had a Buy rating on the stock. On 08/10/2011, UBS had a Buy rating on the stock. On 03/05/2012, Argus had a Buy rating on the stock.

 

“3. Alexion Pharmaceuticals, Inc. (ALXN, Earnings, Analysts, Financials): Engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Market cap at $16.83B, most recent closing price at $87.60. On 12/09/2011, Barclays Capital had an Overweight rating on the stock. On 03/26/2012, Canaccord Genuity had a Buy rating on the stock. On 02/23/2012, UBS had a Buy rating on the stock. On 02/10/2012, Robert W. Baird had an Outperform rating on the stock.

 

“4. Biogen Idec Inc. (BIIB, Earnings, Analysts, Financials): Develops, manufactures, and markets therapeutics in the areas of neurology, immunology, hemophilia, and oncology in the United States and internationally. Market cap at $30.36B, most recent closing price at $126.73. On 12/09/2011, Barclays Capital had an Overweight rating on the stock. On 09/09/2011, UBS had a Buy rating on the stock. On 08/18/2011, Oppenheimer had an Outperform rating on the stock. On 06/21/2011, Deutsche Bank had a Buy rating on the stock.

 

“5. Broadcom Corp. (BRCM, Earnings, Analysts, Financials): Designs and develops semiconductors for wired and wireless communications. Market cap at $17.49B, most recent closing price at $31.74. On 10/13/2011, Robert W. Baird had an Outperform rating on the stock. On 02/02/2012, Canaccord Genuity had a Buy rating on the stock. On 01/09/2012, Deutsche Bank had a Buy rating on the stock.

 

“6. Salesforce.com (CRM, Earnings, Analysts, Financials): Provides customer and collaboration relationship management (CRM) services to various businesses and industries worldwide. Market cap at $18.08B, most recent closing price at $130.99. On 12/06/2011, Barclays Capital had an Overweight rating on the stock. On 11/28/2011, Needham had a Buy rating on the stock. On 05/25/2012, Oppenheimer had an Outperform rating on the stock.

 

“7. Cisco Systems, Inc. (CSCO, Earnings, Analysts, Financials): Designs, manufactures, and sells Internet protocol (IP)-based networking and other products related to the communications and information technology industry worldwide. Market cap at $85.5B, most recent closing price at $15.96. On 10/27/2011, UBS had a Buy rating on the stock. On 12/06/2011, Barclays Capital had an Overweight rating on the stock. On 05/09/2012, Needham had a Buy rating on the stock.

 

“8. Cognizant Technology Solutions Corporation (CTSH, Earnings, Analysts, Financials): Provides information technology consulting and technology services in North America, Europe, and Asia. Market cap at $17.33B, most recent closing price at $56.90. On 10/07/2011, Deutsche Bank had a Buy rating on the stock. On 05/08/2012, Robert W. Baird had a Outperform rating on the stock. On 05/07/2012, Needham had a Buy rating on the stock.

 

“9. LinkedIn Corporation (LNKD, Earnings, Analysts, Financials): Operates an online professional network. Market cap at $9.45B, most recent closing price at $91.51. On 12/29/2011, Collins Stewart had a Buy rating on the stock. On 12/07/2011, Canaccord Genuity had a Buy rating on the stock. On 09/16/2011, Barclays Capital had an Overweight rating on the stock.

 

“10. Ardea Biosciences, Inc. (RDEA, Earnings, Analysts, Financials): Focuses on the discovery and development of small-molecule therapeutics for the treatment of gout and cancer in the United States. Market cap at $1.18B, most recent closing price at $31.90. On 04/12/2012, UBS had a Buy rating on the stock. On 03/26/2012, Canaccord Genuity had a Buy rating on the stock. On 01/19/2012, Collins Stewart had a Buy rating on the stock.

 

“11. Under Armour, Inc. (UA, Earnings, Analysts, Financials): Designs, develops, markets, and distributes a range of apparel and accessories using synthetic microfiber fabrications in the U. Market cap at $4.99B, most recent closing price at $95.75. On 09/23/2011, Argus had a Buy rating on the stock. On 05/09/2012, UBS had a Buy rating on the stock. On 01/31/2012, Needham had a Buy rating on the stock. On 01/03/2012, Robert W. Baird had an Outperform rating on the stock.

 

 

(Written by Ryan Horch. List by Rebecca Lipman. Ratings sources from Reuters.)

 

Use Kapitall's Tools: Looking for ways to analyze this list?

Use this article snapshot as a launch pad (click here for help): Simply click on the links, and use Kapitall's tab navigation to browse through the data…

 

Analyze These Ideas: Getting Started

Dig Deeper: Access Company Snapshots, Charts, Filings

New to Kapitall?

1. New to the site? Click here to register for a free account, and gain access to more tools and data
2. Looking for more investing ideas like this? Click here to sign up for your free copy of Kapitall Weekly
3. Follow us on SeekingAlpha, Motley Fool, Nasdaq and Twitter

 

 

 

playfor100kwirebanner2png

Leave a Reply

Protected by WP Anti Spam

wirebannerscompetepng